NewsDetails

Rachel Darwin, Senior Manager, Public Relations The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society and the Chinese Congress on Holistic Integrative Oncology (2024 CCHIO). XI’ AN, CHINA [November 15, 2024] — The National Comprehensive Cancer Network ® (NCCN ®) — an alliance of leading cancer centers in the United States — is taking part in the Fourth International Congress of the Asian Oncology Society and the Chinese

Read the full article here

Source: www.nccn.org

Categories: Oncologists1, General Medicine News

Tweets with this article

National Comprehensive Cancer Network (NCCN)

NCCN was honored to participate in the 4th International Congress of the Asian Oncology Society and the Chinese Congress on Holistic Integrative Oncology (2024 CCHIO). Learn more: https://t.co/xtnsDwsxCj https://t.co/wtm35Sspo6

Related Articles

Clive Peedell (@drpeedell.bsky.social)

Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality

Clive Peedell November 18, 2024

Ohio State’s Update From the 2024 San Antonio Breast Cancer Symposium 02/01/2025

Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2024 San Antonio…

The James November 18, 2024

Best Practices in Managing Patients on Capivasertib

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on…

OncLive.com November 18, 2024

First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting…

OncLive.com November 18, 2024

Immune checkpoint inhibitor therapy doubles psoriasis risk

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.“Although this adverse effect…

HemOnc Today November 18, 2024

UK-Wide Collaboration to Study Why ICIs Often Fail

The recently launched UK-based MANIFEST collaboration of academic, industry, and National Health Service groups will attempt to understand why less than half of patients respond…

Cancer Discovery November 18, 2024

Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

OncLive.com November 18, 2024

Report on Artificial Intelligence and Health Insurance – Consumer Health Reps at NAIC

This report was compiled by NORC at the University of Chicago on behalf of the Consumer Representatives to the NAIC. The report examines the current…

The Leukemia & Lymphoma Society - Policy Advocacy November 18, 2024

Stem cell transplantation does not increase risk for clonal hematopoiesis

Clonal hematopoiesis did not occur significantly more often among patients who received hematopoietic stem cell transplantation than their donors, according to findings of a correlative…

HemOnc Today November 18, 2024

Merck Buys Bispecific Antibody for up to $3.3 Billion

Today, Merck announced that it will acquire LaNova Medicines’ PD-1/VEGF bispecific antibody, LM-299, for $588 million upfront plus financial awards that could reach $2.7 billion…

Cancer Discovery November 18, 2024